Tezepelumab-ekko (Tezspire)





PATIENT INFORMATION	Referral Status: □ New Referral □ Updated Order □ Order Renewal
Patient Name:	DOB: Patient Phone:
Patient Address:	Patient Email:
Allergies:	☐ NKDA Weight (lbs/kg): Height (in/cm):
Sex: □ M / □ F Date of Last Infusion:	Next Due Date: Preferred Location:
DIACNOSIS (p)	
DIAGNOSIS (Please provide ICD-10 code in spa Severe Persistent Asthma:	ce provided)
Other: Descrip	ation:
Other. Descrip	uon.
THERAPY ADMINISTRATION & DOSING	LABORATORY ORDERS
☑ Administer Tezspire 210mg subcutaneously	☐ Other:
FREQUENCY (Choose one)	PRE-MEDICATION ORDERS
□ Every 4 weeks	☐ Other:
□ Every weeks	
ADDITIONAL ORDERS	NURSING ☑ Hold infusion and notify provider for:
	 current parasitic infection new or worsening asthma symptoms since initiating therapy Recent administration of live vaccines If indicated as required by provider, confirm patient has epinephrine auto-injector and understands indications for use. Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation
PROVIDER INFORMATION	
Preferred Contact Name:	Preferred Contact Email:
Ordering Provider:	Provider NPI:
Referring Practice Name:	Phone: Fax:
Practice Address:	City: State: Zip Code:
Required Documentation: Patient demos, copy of	(Additional documentation required for processing and insurance approval) f front and back of primary and secondary insurance, 2 most recent OVN including ry results, Pulmonary function test, hospitalizations, and flares
•• •	Provider Signature diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availabili